Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + selinexor
- Development stage
- Unknown
- Lead developer
- Karyopharm Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Pembrolizumab + selinexor is a combination drug regimen used in cancer treatment, particularly metastatic non-small cell lung cancer (mNSCLC), metastatic melanoma, and advanced/metastatic colorectal cancer (CRC). Pembrolizumab is an immune checkpoint inhibitor targeting the programmed death-1 (PD-1) receptor, enhancing anti-tumor immune response. Selinexor is an oral selective inhibitor of nuclear export that binds to exportin 1 (XPO1), blocking the transport of tumor suppressor proteins from the nucleus to the cytoplasm, leading to cell cycle arrest and apoptosis. The combination aims to improve antitumor activity by combining immunotherapy with modulation of nuclear export pathways. Clinical studies have shown promising antitumor activity and manageable safety profiles in heavily pretreated patients or those resistant to prior PD-1/PD-L1 therapies.
- Brand names
- Keytruda
- Other names
- pembrolizumab + selinexor
02
Targets
XPO1 (Exportin-1)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + selinexor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + selinexor.